CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
Condition: CLL Interventions: Drug: ibrutinib, venetoclax, obinutuzumab; Drug: ibrutinib, venetoclax Sponsors: Stichting Hemato-Oncologie voor Volwassenen Nederland; Nordic Lymphoma Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Research